- Home
- XBIO vs ULY Comparison
XBIO vs ULY Comparison
Compare XBIO & ULY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIO
- ULY
- Stock Information
- Founded
- XBIO N/A
- ULY 2013
- Country
- XBIO United States
- ULY United States
- Employees
- XBIO N/A
- ULY N/A
- Industry
- XBIO Biotechnology: Pharmaceutical Preparations
- ULY
- Sector
- XBIO Health Care
- ULY
- Exchange
- XBIO Nasdaq
- ULY Nasdaq
- Market Cap
- XBIO 5.8M
- ULY 6.7M
- IPO Year
- XBIO N/A
- ULY N/A
- Fundamental
- Price
- XBIO $2.53
- ULY $4.62
- Analyst Decision
- XBIO Hold
- ULY Strong Buy
- Analyst Count
- XBIO 1
- ULY 1
- Target Price
- XBIO N/A
- ULY $12.00
- AVG Volume (30 Days)
- XBIO 7.1K
- ULY 133.2K
- Earning Date
- XBIO 05-08-2025
- ULY 05-12-2025
- Dividend Yield
- XBIO N/A
- ULY N/A
- EPS Growth
- XBIO N/A
- ULY N/A
- EPS
- XBIO N/A
- ULY N/A
- Revenue
- XBIO $2,500,284.00
- ULY $142,905,000.00
- Revenue This Year
- XBIO $14.23
- ULY N/A
- Revenue Next Year
- XBIO N/A
- ULY $17.87
- P/E Ratio
- XBIO N/A
- ULY N/A
- Revenue Growth
- XBIO N/A
- ULY N/A
- 52 Week Low
- XBIO $2.26
- ULY $2.99
- 52 Week High
- XBIO $5.20
- ULY $32.04
- Technical
- Relative Strength Index (RSI)
- XBIO 25.28
- ULY 46.79
- Support Level
- XBIO $2.26
- ULY $4.52
- Resistance Level
- XBIO $3.43
- ULY $5.20
- Average True Range (ATR)
- XBIO 0.21
- ULY 1.01
- MACD
- XBIO -0.07
- ULY 0.09
- Stochastic Oscillator
- XBIO 16.67
- ULY 43.37
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.
About ULY Urgent.ly Inc.
Urgently Inc is a connected mobility assistance software platform, matching vehicle owners and operators with service professionals who deliver traditional roadside assistance, proactive maintenance and repair services. The traditional experience of a vehicle breakdown is often stressful and inconvenient, compounded by processes that lack transparency and lead to long wait times. Urgently offers an innovative alternative to this traditional experience, leveraging its digitally native software platform to match supply and demand in its network and deliver exceptional mobility assistance experiences at scale.